Colorectal Neoplasms Clinical Trial
Official title:
Repetitive Electrostatic Pressurised Intraperitoneal Aerosol Chemotherapy With Oxaliplatin (ePIPAC-OX) as a Palliative Monotherapy for Isolated Unresectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Single-arm, Phase II Study (CRC-PIPAC)
This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC-OX) as a palliative monotherapy for patients with isolated unresectable colorectal peritoneal metastases.
Rationale: repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with
oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with
isolated unresectable colorectal peritoneal metastases (PM) in several centres worldwide.
However, little is known about its feasibility, safety, tolerability, efficacy, costs, and
pharmacokinetics in this setting.
Objectives: to prospectively explore the feasibility, safety, tolerability, preliminary
efficacy, costs, and pharmacokinetic profile of repetitive ePIPAC-OX as a palliative
monotherapy for isolated unresectable colorectal PM under controlled circumstances.
Study design: multicentre, open-label, single-arm, phase II study.
Setting: two Dutch tertiary referral hospitals for the surgical treatment of colorectal PM.
Study population: adults who have a World Health Organisation (WHO) performance status of 0
or 1, adequate organ functions, histologically or cytologically confirmed unresectable PM of
a colorectal or appendiceal carcinoma, no systemic metastases, no symptoms of
gastrointestinal obstruction, no contraindications for the planned intervention, and no
previous pressurised intraperitoneal aerosol chemotherapy (PIPAC).
Intervention: instead of standard palliative treatment, enrolled patients receive
laparoscopy-controlled ePIPAC-OX (92 mg/m2 body-surface area [BSA]) with intravenous
leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four
weeks after each procedure, patients undergo clinical, radiological, and biochemical
evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease
progression, after which standard palliative treatment is (re)introduced.
Outcomes: the primary outcome is the number of patients with major toxicity (grade ≥3
according to the Common Terminology Criteria for Adverse Events v4.0) up to four weeks after
the last procedure. Secondary outcomes are the environmental safety of ePIPAC-OX,
procedure-related characteristics, the number of procedures in each patient and reasons for
discontinuation, minor toxicity, organ-specific toxicity, postoperative complications,
hospital stay, readmissions, quality of life, costs, progression-free survival, overall
survival, and the radiological, histopathological, cytological, biochemical, and macroscopic
tumour response. Atomic absorption spectrophotometry is used to measure concentrations of
oxaliplatin in plasma, plasma ultrafiltrate, urine, ascites, PM, and normal peritoneum during
and after ePIPAC-OX.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |